Akido Labs Aims to Bridge Healthcare Gaps with $60M Investment
Akido Labs, a leading health technology company, has raised $60 million in a Series B funding round.
The round was led by Oak HC/FT, with participation from notable investors including Greco, SNR, Y Combinator, Jeff Dean (Chief Scientist at Google DeepMind & Google Research), and Future Communities Capital.
The new funding will be utilized to expand Akido’s AI driven clinical platform, ScopeAI. Designed to assist healthcare providers, ScopeAI captures patient responses, generates relevant clinical questions, and drafts comprehensive documents, including treatment plans and diagnoses.
Akido Labs Targets Chronic Care with Fresh $60M Investment
The system is built with continuous learning capabilities, allowing it to improve accuracy and efficiency based on user feedback.
Founded in 2015 by Prashant Samant, Jared Goodner, Sanjit Mahanti, and Hugh Gordon, Akido Labs is focused on enhancing the efficiency of healthcare delivery through AI integration in clinical workflows.
Currently, ScopeAI is deployed in nearly 100 clinics, enhancing patient-provider interactions and improving clinical outcomes. “Our mission is to close the gaps in healthcare delivery by empowering providers to work more efficiently,” said Prashant Samant, Co-Founder and CEO of Akido Labs.
“With this new funding, we aim to expand our reach to more clinics, enhance ScopeAI’s capabilities, and enter new markets.”
Additionally, the company is set to launch a healthcare initiative in New York City, targeting chronic diseases among professional drivers, further emphasizing Akido’s commitment to democratizing access to quality healthcare.
